QT Imaging Holdings, Inc.

QT Imaging Holdings, Inc. is a medical device company dedicated to the research, development, and commercialization of innovative body imaging systems that utilize low-frequency sound waves. Headquartered in Novato, California, the company's mission is to deliver precision imaging without compromise, aiming to improve global health outcomes by providing safe, affordable, accessible, and patient-centered medical imaging solutions.

The company's primary products include the QTI Breast Acoustic CT™ Scanner and its proprietary QTviewer software. The QTI Breast Acoustic CT™ Scanner is a unique ultrasonic imaging system that provides true 3D, sub-millimeter resolution images of a patient's breast using transmission and reflection ultrasound, notably without ionizing radiation, compression, or contrast agents. The QTviewer software is an image viewing and analysis platform designed to interpret the rich, quantitative datasets generated by the scanner, enabling radiologists to interact dynamically with entire breast volumes. QT Imaging focuses on addressing critical clinical gaps in breast health, particularly for women with dense breast tissue or those with contraindications for MRI.

Led by CEO Raluca Dinu, QT Imaging Holdings, Inc. became publicly traded on NASDAQ under the ticker "QTI" in March 2024, following a business combination with GigCapital5. Recent notable developments include receiving FDA 510(k) clearance in March 2026 for an enhanced configuration of its Breast Acoustic CT scanner to improve posterior breast tissue visualization. The company also achieved a significant reimbursement milestone with the American Medical Association's approval of a new Category III CPT code for 3D breast ultrasound tomography, effective January 1, 2027. Furthermore, QT Imaging has expanded its global reach by securing UAE regulatory clearance and an exclusive distribution deal with Al Naghi Medical, projecting a $24 million revenue pipeline through 2028.